Media

Latest news and press releases

21 April 2025
K-679: A Novel Antibody Drug-loaded Unimicelle Conjugate with Ultra-High Drug Loading Capacity Demonstrates Superior Efficacy in EGFR-Expressing Solid Tumors. https://www.prnewswire.co.uk/news-releases/k-679-a-novel-antibody-drug-loaded-unimicelle-conjugate-with-ultra-high-drug-loading-capacity-demonstrates-superior-efficacy-in-egfr-expressing-solid-tumors-302430671.html

2 April 2025
The Ferrari Formula One team have agreed a multi-year deal with Espacio, a hotel company that forms part of the Kowa group. https://www.ferrari.com/en-GM/formula1/articles/espacio-joins-ferrari-as-official-partner?amp=true

April 06, 2023
Initiation of a new Phase 3 global clinical study for the indication of Fuchs endothelial corneal dystrophy [Developmental code: K-321]
March 22, 2023
Initiation of a new Phase 3 global clinical study for the indication of Fuchs endothelial corneal dystrophy [Developmental code: K-321]
December 16, 2022
Adani & Kowa Strengthen Business Alliance with Multiple Agreements
August 26, 2022
Initiation of Phase 3 clinical study in the United States Indication for Fuchs endothelial corneal dystrophy [ Development code: K-321]
March 22, 2022
Kowa, Adani Power & IHI collaborate for Ammonia Co-firing in Thermal Power Plants in India

January 06, 2021
Kowa Company, Ltd. has renewed its corporate website. Take a look at the fresh new website here: https://www.kowa.co.jp/eng

September 28, 2020
Kowa Pharmaceutical Europe Co. Ltd. Press Release : Dr. Rod Coombs announced as President.
August 26, 2020
K-115 (Ripasudil Hydrochloride Hydrate), a Rho Kinase Inhibitor, has been approved in Thailand
July 13, 2020
K-115 (Ripasudil Hydrochloride Hydrate), a Rho Kinase Inhibitor, has been approved in Malaysia
March 11, 2020
K-115 (Ripasudil Hydrochloride Hydrate), a Rho Kinase Inhibitor, has been approved in Singapore
February 19, 2020
Fixed Combination Eye Drop of Ripasudil Hydrochloride Hydrate, a Rho Kinase Inhibitor, and Brimonidine Tartrate Started Phase 3 Clinical Studies in Japan [Developmental code: K-232]

This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. Find out more

You are now leaving the kowapharmaceuticals.eu website.

This link will take you to a third party website to which our Privacy policy does not apply. You are solely responsible for your interactions with any third party website. We encourage you to read the privacy policy of every website you visit.

CONTINUE TO THIRD PARTY WEBSITE

Report adverse event

Kowa routinely monitors the safety of all its medicines. This includes review of safety data from clinical studies, and collection of reports and cases of adverse events for marketed products.

Patients and Volunteers in clinical trials reporting an adverse event must contact the investigator.

For specific medical information requests please visit the relevant product page to get in touch.

For the reporting of Livazo adverse events within Europe Union please contact local distributor or Recordati

For the reporting of Livazo adverse events within Middle East and North Africa (MENA) please contact...

Contact us






    I confirm I have read and accept the terms of the Privacy policy